Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Oct 13, 2026
Biodexa Pharmaceuticals filed Prospectus Supplement No. 5 to its F-1 resale prospectus covering 17,150 ordinary shares (343 ADSs) held by selling shareholders. The supplement incorporates a 6-K announcing that the ADS ratio changes from 1 ADS per 50 ordinary shares to 1 ADS per 400 ordinary shares, effective on or about October 26, 2026. ADS holders must mandatorily exchange 8 old ADSs (CUSIP 59564R872) for 1 new ADS (CUSIP 59564R864) via depositary JPMorgan Chase, with the same effect as a one-for-eight reverse ADS split; the ordinary shares are unaffected.
Key figures
- New cusip
- 59564R864
- Old cusip
- 59564R872
- New ads ratio
- 1 ADS = 400 ordinary shares
- Old ads ratio
- 1 ADS = 50 ordinary shares
- Resale ads count
- 343
- Last closing price usd
- 0.3832
- Resale shares ordinary
- 17150
- Reverse adss split ratio
- 1-for-8
- Ratio change effective date
- 2026-10-26
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.